How Celgene and Bristol Myers Squibb Used Volume Restrictions to Delay Revlimid Competition
The Folly of Hoarding Knowledge in the COVID-19 Age
Patents, Licenses and Drug Prices
Under pressure, Gilead expands Sovaldi licensing deal to four middle-income countries
WHO moves to widen access to generic Sovaldi in dozens of countries
Voluntary License Scorecard
Implications of the Patent Pool Licenses With Gilead (Part II)
Implications of the Patent Pool Licenses with Gilead